ARCTArcturus Therapeutics Holdings Inc.
$6.82-49% 1Y
$6.82
$5.5252 weeks$23.16
ARCT in its own filings
ARCT's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
157
Events found in the filings · across 413 filings · the record starts in 2019
- Hard flags
- 1
Hard flags
- Most recent filing
- Sep 23, 2026
Most recent filing · Form 8-K
- Record starts
- Apr 11, 2019
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- Change in certifying accountantpast_3y
- 2024-04-05
- Late periodic report2 occurrences
- 2025-11-12
- SEC comment-letter activity9 occurrences
- 2022-12-30
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress.Earnings release · press release
- Jul 2, 2026On June 26, 2026, Arcturus Therapeutics, Inc. (“Arcturus”), a wholly-owned subsidiary of Arcturus Therapeutics Holdings Inc., a Delaware corporation (the “Company”), entered into a series of agreements with Thermo Fisher Scientific Inc. (“Thermo Fisher”) and certain of Thermo Fisher’s affiliates to establish a …Material agreement entered · Form 8-K
- May 7, 2026Effective May 1, 2026, Dennis Mulroy, 71, was appointed Chief Financial Officer of the Company. Mr. Mulroy will become the Company’s principal financial officer on the date immediately following the date on which the Company files its Quarterly Report on Form 10-Q for the period ended March 31, 2026.Earnings release · Form 8-K
- Mar 3, 2026Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress.Earnings release · press release
- Dec 15, 2025On December 11, 2025, Arcturus Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) and Andy Sassine, Chief Financial Officer of the Company and a member of the Company’s Board of Directors (the “Board”), mutually agreed to end their employment relationship in an amicable manner effective December 31 …Director or officer change · Form 8-K
- Nov 10, 2025Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress.Earnings release · press release
- Oct 22, 2025Recent Events Release of Data On October 22, 2025, the Company announced interim results from its ongoing Phase 2 clinical trial of ARCT-032, an investigational inhaled mRNA therapy for cystic fibrosis (CF)Regulation FD disclosure · Form 8-K
- Sep 26, 2025Meiji Seika Pharma Launches Two-Dose Vial of.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…